sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
antidepressants
|
Type 1C antiarrhythmics
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p16
|
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
|
ketoconazole
|
corticosteroids
|
MECHANISM
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s2
|
DDI-DrugBank.d487.s2.p2
|
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
|
Vardenafil
|
indinavir
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s37
|
DDI-DrugBank.d198.s37.p0
|
HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
|
TRICOR
|
HMG-CoA reductase inhibitors
|
ADVISE
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s3
|
DDI-DrugBank.d283.s3.p2
|
Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
|
vitamin D analogues
|
corticosteroids
|
MECHANISM
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s11
|
DDI-DrugBank.d384.s11.p2
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
valproic acid
|
phenobarbital
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p75
|
Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
|
allopurinol
|
chlorpropamide
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s20
|
DDI-DrugBank.d413.s20.p9
|
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
|
digitalis preparations
|
morphine
|
NONE
|
Dobutamine_ddi.xml
|
DDI-DrugBank.d274.s3
|
DDI-DrugBank.d274.s3.p18
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
diltiazem
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p61
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
barbiturates
|
CMI
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p19
|
Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
|
quinolones
|
cyclosporine
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s14
|
DDI-DrugBank.d562.s14.p2
|
Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
|
CAMPTOSAR
|
dexamethasone
|
EFFECT
|
Irinotecan_ddi.xml
|
DDI-DrugBank.d279.s3
|
DDI-DrugBank.d279.s3.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
granisetron
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p26
|
Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
|
Probenecid
|
ciprofloxacin
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s15
|
DDI-DrugBank.d123.s15.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Atromid-S
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p19
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
barbiturates
|
barbiturates
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p68
|
Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
|
Nitrates
|
nitrates
|
NONE
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s1
|
DDI-DrugBank.d373.s1.p1
|
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
|
Antihistamines
|
barbiturates
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s0
|
DDI-DrugBank.d389.s0.p1
|
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
|
nonsteroidal anti-inflammatory agents
|
coumarin-type anticoagulants
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s1
|
DDI-DrugBank.d415.s1.p4
|
Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
|
entacapone
|
levodopa
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s6
|
DDI-DrugBank.d455.s6.p0
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
glucocorticoids
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p8
|
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
|
Azlocillin
|
amikacin
|
ADVISE
|
Azlocillin_ddi.xml
|
DDI-DrugBank.d9.s0
|
DDI-DrugBank.d9.s0.p0
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
CNS depressants
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p0
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
enflurane
|
aminoglycosides
|
NONE
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p13
|
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
|
retinyl acetate
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s0
|
DDI-MedLine.d12.s0.p3
|
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
|
Sumatriptan
|
selective serotonin reuptake inhibitor
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s16
|
DDI-DrugBank.d568.s16.p0
|
Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
|
TRACLEER
|
glyburide
|
ADVISE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s18
|
DDI-DrugBank.d289.s18.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
multivitamins
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p9
|
Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
|
Quinolones
|
warfarin
|
EFFECT
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s5
|
DDI-DrugBank.d427.s5.p2
|
Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
|
Heparin
|
heparin
|
NONE
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s0
|
DDI-DrugBank.d148.s0.p3
|
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
|
iodine
|
Carbimazole
|
NONE
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s0
|
DDI-DrugBank.d213.s0.p6
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
corticosteroids
|
salbutamol
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p5
|
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
|
ketoconazole
|
cisapride
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s8
|
DDI-DrugBank.d165.s8.p0
|
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
|
ruthenium red
|
InsP(3)
|
NONE
|
11137703.xml
|
DDI-MedLine.d114.s1
|
DDI-MedLine.d114.s1.p2
|
Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
|
clonidine
|
agents with b-blocking properties
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s4
|
DDI-DrugBank.d269.s4.p2
|
Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
|
belladonna alkaloids
|
cisapride
|
EFFECT
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s3
|
DDI-DrugBank.d237.s3.p8
|
The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
|
nitrofurantoin
|
magnesium trisilicate
|
MECHANISM
|
Nitrofurantoin_ddi.xml
|
DDI-DrugBank.d276.s1
|
DDI-DrugBank.d276.s1.p0
|
Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
|
Auranofin
|
Cuprimine
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s1
|
DDI-DrugBank.d374.s1.p2
|
Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
|
corticosteroids
|
warfarin
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s6
|
DDI-DrugBank.d314.s6.p3
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
amiodarone
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p48
|
Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
|
celecoxib
|
warfarin
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s22
|
DDI-DrugBank.d172.s22.p3
|
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
|
fexofenadine hydrochloride
|
antacid
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s19
|
DDI-DrugBank.d466.s19.p8
|
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
|
phenothiazines
|
levodopa
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s2
|
DDI-DrugBank.d47.s2.p8
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
VIDEX
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p14
|
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
|
NSAIDs
|
lithium
|
EFFECT
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s18
|
DDI-DrugBank.d219.s18.p0
|
Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
|
Chloramphenicol
|
beta-lactam antibiotics
|
EFFECT
|
Ceftazidime_ddi.xml
|
DDI-DrugBank.d122.s3
|
DDI-DrugBank.d122.s3.p0
|
Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
|
Anafranil
|
sympathomimetic drugs
|
ADVISE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s3
|
DDI-DrugBank.d238.s3.p1
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
H2 Blockers
|
famotidine
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p3
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
|
TRACRIUM
|
enflurane
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s0
|
DDI-DrugBank.d469.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
haloperidol
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p19
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
fluvoxamine
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p1
|
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
|
Amitriptyline
|
barbiturates
|
NONE
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s2
|
DDI-DrugBank.d495.s2.p3
|
Therefore, concurrent use of aspirin and ketoprofen is not recommended.
|
aspirin
|
ketoprofen
|
ADVISE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s8
|
DDI-DrugBank.d499.s8.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
protease inhibitors
|
risperidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p970
|
Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
|
carbamazepine
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s13
|
DDI-DrugBank.d87.s13.p5
|
Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
|
cefdinir
|
iron
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s5
|
DDI-DrugBank.d420.s5.p14
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
calcium channel blockers
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p15
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
diclofenac
|
cyclosporine
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p4
|
Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
|
antacids
|
diflunisal
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s9
|
DDI-DrugBank.d132.s9.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
lithium
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p11
|
Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
|
levamisole
|
warfarin sodium
|
ADVISE
|
Levamisole_ddi.xml
|
DDI-DrugBank.d381.s2
|
DDI-DrugBank.d381.s2.p0
|
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
|
ketamine
|
halothane
|
MECHANISM
|
1115367.xml
|
DDI-MedLine.d16.s5
|
DDI-MedLine.d16.s5.p0
|
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
|
cimetidine
|
IRESSA
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s7
|
DDI-DrugBank.d207.s7.p5
|
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
|
Vardenafil
|
alpha-blocker
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s35
|
DDI-DrugBank.d198.s35.p0
|
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
|
phenytoin
|
aminopyrine
|
NONE
|
Famotidine_ddi.xml
|
DDI-DrugBank.d203.s2
|
DDI-DrugBank.d203.s2.p10
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
flecainide
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p15
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
succinimides
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p17
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
chlordiazepoxide
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p10
|
Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
|
chloroquine
|
carbamazepine
|
EFFECT
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s16
|
DDI-DrugBank.d94.s16.p4
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
Phenytoin
|
triazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p952
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
mefenamic acid
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p10
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
5-fluorouracil
|
glucocorticoids
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p99
|
The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
|
guanfacine
|
phenytoin
|
MECHANISM
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s1
|
DDI-DrugBank.d507.s1.p1
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluvoxamine
|
paroxetine
|
NONE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p15
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
carbamazepine
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p12
|
When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
|
antihypertensive drugs
|
diazoxide
|
EFFECT
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s1
|
DDI-DrugBank.d31.s1.p0
|
The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
|
proton pump inhibitors
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s12
|
DDI-DrugBank.d48.s12.p2
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
corticosteroids
|
sympathomimetics
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p24
|
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
|
prednisolone
|
warfarin
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s18
|
DDI-DrugBank.d249.s18.p9
|
As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
|
alcohol
|
ABILIFY
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s28
|
DDI-DrugBank.d509.s28.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ibuprofen
|
quinidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p976
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
didanosine
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p44
|
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
|
naloxone
|
morphine
|
EFFECT
|
3155550.xml
|
DDI-MedLine.d63.s6
|
DDI-MedLine.d63.s6.p1
|
Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
|
eprosartan
|
ketoconazole
|
NONE
|
Eprosartan_ddi.xml
|
DDI-DrugBank.d525.s2
|
DDI-DrugBank.d525.s2.p0
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
magnesium hydroxide
|
fosinopril
|
MECHANISM
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p25
|
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.
|
NovoLog
|
NPH human insulin
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s7
|
DDI-DrugBank.d313.s7.p0
|
ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
|
NSAIDs
|
ACE-inhibitors
|
EFFECT
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s0
|
DDI-DrugBank.d219.s0.p2
|
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
|
colestipol hydrochloride
|
digitoxin
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s14
|
DDI-DrugBank.d345.s14.p4
|
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
|
non-nucleoside reverse transcriptase inhibitor
|
protease inhibitor
|
NONE
|
11217868.xml
|
DDI-MedLine.d132.s1
|
DDI-MedLine.d132.s1.p2
|
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
|
diclofenac
|
hypoglycemic agents
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s13
|
DDI-DrugBank.d249.s13.p1
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
ergot derivatives
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p114
|
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
|
lithium
|
ACE inhibitors
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s18
|
DDI-DrugBank.d334.s18.p5
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
itraconazole
|
zonisamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p758
|
Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
|
Panretin
|
DEET
|
ADVISE
|
Alitretinoin_ddi.xml
|
DDI-DrugBank.d392.s0
|
DDI-DrugBank.d392.s0.p0
|
Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
|
calcium channel blockers
|
digoxin
|
EFFECT
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s12
|
DDI-DrugBank.d450.s12.p2
|
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
|
SSRI
|
TCA
|
INT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s11
|
DDI-DrugBank.d386.s11.p0
|
Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
|
Digitalis
|
digoxin
|
NONE
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s2
|
DDI-DrugBank.d373.s2.p3
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
zinc
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p8
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
acetaminophen
|
valproic acid
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p61
|
Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
|
OCs
|
macrolide antibiotics
|
NONE
|
Adinazolam_ddi.xml
|
DDI-DrugBank.d449.s2
|
DDI-DrugBank.d449.s2.p6
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.